Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus

Journal of Infectious Diseases

Volumn 212, Issue 7, 2015, Pages 1022-1031

  Laing, Kerry J ^a   Russell, Ronnie M ^a   Dong, Lichun ^a   Schmid, D Scott ^b   Stern, Michael ^c   Magaret, Amalia ^c,d,e   Haas, Jurgen G ^f   Johnston, Christine ^a,e   Wald, Anna ^a,c,e   Koelle, David M ^a,c,d,e,g  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Department of Laboratory Medicine ^*  (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Epitopes; T lymphocytes; vaccine; varicella zoster virus

Indexed keywords

EPITOPE; GLYCOPROTEIN E; VARICELLA ZOSTER VACCINE; VIRUS PROTEIN; LIVE VACCINE;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; EX VIVO STUDY; HERPES ZOSTER; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINATION; AMINO ACID SEQUENCE; IMMUNOLOGY; MIDDLE AGED; MOLECULAR GENETICS; VARICELLA ZOSTER VIRUS;

AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; MOLECULAR SEQUENCE DATA; VACCINATION; VACCINES, ATTENUATED;

EID: 84943415460     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv164     Document Type: Article

References (49)

1. Breuer J, Pacou M, Gautier A, Brown MM. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology 2014; 83:e27-33.
2. Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis 2014; 58:1497-503.
3. WHO. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec 2014; 89:265-87.
4. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc 2007; 107:S2-7.
5. Goldman GS, King PG. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine 2013; 31:1680-94.
6. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
7. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8.
8. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160-6.
9. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLOSMed 2013; 10:e1001420.
10. Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis 2013; 208:1375-85.
11. Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280-90.
12. Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age. J Infect Dis 2013; 208:1953-61.
13. Patterson-Bartlett J, Levin MJ, Lang N, Schodel FP, Vessey R, Weinberg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 2007; 25:7087-93.
14. Levin MJ, Schmader KE, Gnann JW, et al. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis 2013; 208:1386-90.
15. Gilbert PB, Gabriel EE, Miao X, et al. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 2014; 210:1573-81.
16. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35.
17. Laing KJ, Magaret AS, Mueller DE, et al. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol 2010; 30:703-22.
18. Weinmann S, Chun C, Mullooly JP, et al. Laboratory diagnosis and characteristics of breakthrough varicella in children. J Infect Dis 2008; 197(suppl 2):S132-8.
19. Smith AG, Pyo CW, NelsonW, et al. Next generation sequencing to determine HLA class II genotypes in a cohort of hematopoietic cell transplant patients and donors. Hum Immunol 2014; 75:1040-6.
20. Ceroni A, Sibani S, Baiker A, et al. Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a selfassembled protein microarray. Mol Biosyst 2010; 6:1604-10.
21. Jing L, Haas J, Chong TM, et al. Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest 2012; 122:654-73.
22. Cohen JI. The varicella-zoster virus genome. Curr Top Microbiol Immunol 2010; 342:1-14.
23. Koelle DM, Corey L, Burke RL, et al. Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 1994; 68:2803-10.
24. Braun RP, Payne LG, Dong L. Characterization of the IFN-gamma Tcell responses to immediate early antigens in humans with genital herpes. Virol J 2006; 3:54.
25. Moss NJ, Magaret A, Laing KJ, et al. Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes. J Virol 2012; 86:9952-63.
26. Koelle DM. Expression cloning for the discovery of viral antigens and epitopes recognized by T-cells. Methods 2003; 29:213-26.
27. Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol 2001; 166:4049-58.
28. Jing L, McCaughey SM, Davies DH, et al. ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods 2009; 347:36-45.
29. Chung N, Zhang XD, Kreamer A, et al. Median absolute deviation to improve hit selection for genome-scale RNAi screens. J Biomol Screen 2008; 13:149-58.
30. Ouwendijk WJ, Laing KJ, Verjans GM, Koelle DM. T-cell immunity to human alphaherpesviruses. Curr Opin Virol 2013; 3:452-60.
31. Laing KJ, Dong L, Sidney J, Sette A, Koelle DM. Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol 2012; 167:47-58.
32. Ouwendijk WJ, Geluk A, Smits SL, Getu S, Osterhaus AD, Verjans GM. Functional characterization of ocular-derived human alphaherpesvirus cross-reactive CD4 T cells. J Immunol 2014; 192:3730-9.
33. Weinberg A, Levin MJ. VZV T cell-mediated immunity. In: Abendroth A, Arvin AM, Moffat JF, eds. Varicella-zoster virus. Current topics in microbiology and immunolog. Vol 342. Berlin: Springer, 2010: 341-57.
34. Vukmanovic-Stejic M, Sandhu D, Sobande TO, et al. Varicella zosterspecific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge in humans. J Immunol 2013; 190:977-86.
35. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIVinfected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015; 211:1279-87.
36. Kleemann P, Distler E, Wagner EM, et al. Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation. Haematologica 2012; 97:874-82.
37. Jones L, Black AP, Malavige GN, Ogg GS. Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection. J Virol 2006; 80:9772-8.
38. Vita R, Zarebski L, Greenbaum JA, et al. The immune epitope database 2.0. Nucleic Acids Res 2010; 38:D854-62.
39. Huang Z, Vafai A, Lee J, Mahalingam R, Hayward AR. Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones. J Virol 1992; 66:2664-9.
40. Sadzot-Delvaux C, Arvin AM, Rentier B. Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J Infect Dis 1998; 178(suppl 1):S43-7.
41. Arvin AM, Gilden D. Varicella-zoster virus. In: Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B, eds. Fields Virology. Vol. 2. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins, 2013:2015-57.
42. Kennedy PG, Cohrs RJ. Varicella-zoster virus human ganglionic latency: a current summary. J Neurovirol 2010; 16:411-8.
43. Levin MJ. Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol 2014; 61:487-95.
44. Zhu J, Peng T, Johnston C, et al. Immune surveillance by CD8alphaalpha+ skin-resident T cells in human herpes virus infection. Nature 2013; 497:494-7.
45. van Velzen M, Jing L, Osterhaus AD, Sette A, Koelle DM, Verjans GM. Local CD4 and CD8 T-cell reactivity to HSV-1 antigens documents broad viral protein expression and immune competence in latently infected human trigeminal ganglia. PLOS Pathog 2013; 9:e1003547.
46. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998; 101:1500-8.
47. Jones L, Black AP, Malavige GN, Ogg GS. Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur J Immunol 2007; 37:3393-403.
48. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 2008; 152:522-31.
49. Vermeulen JN, Lange JM, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >/=60 years of age. Vaccine 2012; 30:904-10.